INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
INmune Bio and Quantum Computing Inc. announced a collaboration applying quantum optimization, AI and data analytics to find new indications and biomarkers for XPro, INMB's investigational soluble-TNF inhibitor for Alzheimer's and other conditions. The engagement uses INMB's clinical dataset from four trials alongside QCi's Dirac-3S machine, and marks QCi's first commercial customer in pharma and biotech; no financial terms were disclosed.
Key figures
- Clinical trials data
- data spanning pre-clinical research through four clinical trials
- First pharma customer
- QCi's first commercial customer in pharmaceutical and biotechnology markets
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.